- Home
- / Lepu Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lepu Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.1
2024-10-29
Market Capitalization
$5.2 B
2024-10-29
Revenue
¥934.9 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 15.6M | 225.4M | 367.8M | 934.9M | |||
| Cost of goods sold | 2.0M | 28.3M | 74.8M | 89.6M | |||
| Gross profit | 3.5M | 2.9M | 5.6M | 24.7M | 204.2M | 301.5M | 852.5M |
| Gross profit margin, % | 158.5% | 90.6% | 82.0% | 91.2% | |||
| Operating expense total | 372.4M | 366.0M | 853.3M | 570.1M | 485.5M | 575.5M | 661.8M |
| Depreciation and amortization | 49.3M | 84.1M | 95.2M | 95.4M | 102.6M | 100.2M | 93.7M |
| EBITDA | (377.5M) | (375.2M) | (865.4M) | (577.7M) | (308.6M) | (290.5M) | 183.1M |
| EBITDA margin, % | -3709.9% | -136.9% | -79.0% | 19.6% | |||
| EBIT | (426.7M) | (459.3M) | (961.6M) | (673.9M) | (197.5M) | (412.5M) | 19.8M |
| EBIT margin, % | -4327.9% | -87.6% | -112.2% | 2.1% | |||
| Interest income | 396.0K | 5.3M | 4.1M | 45.9M | 8.3M | 4.7M | 5.3M |
| Interest expense | 52.6M | 86.3M | 3.3M | 8.6M | 16.0M | 23.0M | 29.3M |
| Pre tax profit | (515.5M) | (613.4M) | (1.0B) | (699.4M) | (30.3M) | (424.2M) | 260.6M |
| Income tax expense | 1.8M | ||||||
| Net Income | (515.5M) | (613.4M) | (1.0B) | (699.4M) | (30.3M) | (424.2M) | 258.9M |